文献速递肿瘤 PET/CT

PET/CT用于其他淋巴瘤治疗后的反应评估、自体干细胞移植前的反应评估及淋巴瘤随访

PET/CT for Lymphoma Post-therapy Response Assessment in Other Lymphomas, Response Assessment for Autologous Stem Cell Transplant, and Lymphoma Follow-up.
PubMed 文献 · Semin Nucl Med · 2017-11-06

本文综述FDG-PET/CT在霍奇金淋巴瘤和弥漫大B细胞淋巴瘤以外其他常见FDG亲和淋巴瘤中的价值,包括滤泡性淋巴瘤、套细胞淋巴瘤和外周T细胞淋巴瘤的治疗后反应评估、自体干细胞移植前评估及治疗后随访。滤泡性淋巴瘤治疗后FDG-PET/CT较CT更敏感和特异,且对无进展生存和总生存的预测优于常规CT评估。套细胞淋巴瘤和外周T细胞淋巴瘤的数据显示FDG-PET/CT在治疗后评估中的获益结果不一,而监测价值因假阳性率高及准确性依赖监测时机和淋巴瘤亚型而数据混杂。

要点

  • 滤泡性淋巴瘤FDG亲和且摄取范围广,通常与组织学分级相关。
  • 滤泡性淋巴瘤治疗后FDG-PET/CT较CT更敏感和特异,对生存预测优于CT。
  • 套细胞淋巴瘤和外周T细胞淋巴瘤治疗后FDG-PET/CT获益数据不一,监测价值数据混杂。

核心结论

  • FDG-PET/CT是霍奇金淋巴瘤和弥漫大B细胞淋巴瘤分期及治疗后反应评估的成熟一线影像工具。
  • 许多指南和Lugano分类不推荐FDG-PET/CT作为非霍奇金、非弥漫大B细胞淋巴瘤亚型治疗反应评估的一线诊断工具。
  • 滤泡性淋巴瘤治疗后FDG-PET/CT较CT更敏感和特异,且对无进展生存和总生存的预测优于常规CT评估。
  • 套细胞淋巴瘤和外周T细胞淋巴瘤治疗后FDG-PET/CT获益数据不一,监测价值因假阳性率高及准确性依赖监测时机和亚型而数据混杂。

研究设计与样本

  • 综述,检索范围未在摘要中报告。

主要发现

  • 滤泡性淋巴瘤最常见FDG亲和,摄取范围广,通常与组织学分级相关,后者是侵袭性和预后的主要决定因素。
  • 滤泡性淋巴瘤治疗后FDG-PET/CT较CT更敏感和特异,对无进展生存和总生存的预测优于常规CT评估。
  • FDG-PET/CT对套细胞淋巴瘤分期有用,但治疗后反应评估中较常规CT的获益数据结果不一。
  • 外周T细胞淋巴瘤常FDG亲和,治疗后FDG-PET/CT结果在许多亚型中具有重要预后价值和治疗意义。
  • 治疗后FDG-PET/CT较常规CT更能确定淋巴瘤的化疗敏感性,因此更能预测哪些患者从自体干细胞移植中获益更大。

关键数值与推荐

  • 许多指南和Lugano分类不推荐FDG-PET/CT作为非霍奇金、非弥漫大B细胞淋巴瘤亚型治疗反应评估的一线诊断工具。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 套细胞淋巴瘤治疗后反应评估中FDG-PET/CT较常规CT的获益数据结果不一。
  • FDG-PET/CT用于治疗后监测的价值数据混杂,因报告假阳性率高且准确性取决于监测持续时间或时机及淋巴瘤亚型。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

FDG-PET/CT is an established first-line diagnostic imaging tool used in the staging of most lymphomas and for post-therapy response assessment in Hodgkin lymphoma (HL) and diffuse large B-cell lymphoma (DLBCL). Many of the subtypes of lymphoid neoplasms classified by the World Health Organization demonstrate significant FDG-avidity or uptake; however, many guidelines and Lugano classification do not recommend the use of FDG-PET/CT in assessing response to therapy for these non-HL, non-DLBCL subtypes as a first-line diagnostic tool. This article reviews the role of FDG-PET/CT in the evaluation of the other most common "FDG-avid" lymphomas than HL and DLBCL, the role of FDG-PET/CT before autologous stem cell transplant, and for post-treatment follow-up. Follicular lymphoma is most commonly FDG-avid with a wide range of uptake that generally correlates with the histologic grade, a major determinant of aggressiveness and prognosis. FDG-PET/CT is more sensitive and specific than CT for detecting residual disease post therapy for both aggressive and indolent follicular lymphoma. Post-treatment FDG-PET/CT for follicular lymphoma has significant prognostic value, that is, better predicts progression-free and overall survival than does conventional post-treatment assessment with CT. FDG-PET/CT is useful in the staging of mantle cell lymphoma, a very aggressive, incurable subtype of lymphoma; however, data show mixed results on the benefits of FDG-PET/CT over conventional CT assessment in post-therapy response evaluation. Peripheral T-cell lymphomas, a rare aggressive group of T-cell lymphomas, are often FDG-avid. Post-therapy FDG-PET/CT results have major prognostic value and therapeutic implications in many subtypes of peripheral T-cell lymphomas. Post-treatment FDG-PET/CT is superior to conventional CT for determining chemosensitivity of lymphoma, and therefore is better able to predict which patients will have a greater benefit or outcome with autologous stem cell transplant. There are mixed data on the value of FDG-PET/CT for surveillance after treatment because of high reported false-positive rates and accuracy that depends on the duration or timing of surveillance and the subtype of lymphoma.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Karls S, Shah H, Jacene H, et al. PET/CT for Lymphoma Post-therapy Response Assessment in Other Lymphomas, Response Assessment for Autologous Stem Cell Transplant, and Lymphoma Follow-up. Semin Nucl Med. 2017. PMID: 29195616. doi:10.1053/j.semnuclmed.2017.09.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。